Source link : https://www.newshealth.biz/health-news/new-treatment-approved-for-chronic-inflammatory-demyelinating-polyneuropathy/
The FDA expanded the indication of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) Friday to include treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), drugmaker argenx announced. The FDA’s decision marked a “groundbreaking day” for CIDP treatment, said Jeffrey Allen, MD, of the University of Minnesota in Minneapolis, a principal investigator for the drug’s pivotal […]
Author : News Health
Publish date : 2024-06-23 18:39:11
Copyright for syndicated content belongs to the linked Source.
Categories